Previous 10 | Next 10 |
10x Genomics (NASDAQ: TXG ): Q1 GAAP EPS of -$0.22 misses by $0.09 . More news on: 10x Genomics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
PLEASANTON, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the quarter ended March 31, 2020. Recent Highlights Revenue of $71.9 million for the first quarter, representing a 34% increase over the corresponding period of...
PLEASANTON, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Wednesday, May 13 at 8:00 a.m. Pacif...
PLEASANTON, Calif., April 24, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020. The company’s management will webcast a corresponding conference call beginning at...
Citing COVID-19 disruptions, 10x Genomics (NASDAQ: TXG ) has withdrawn its 2020 guidance issued on February 18. More news on: 10x Genomics, Inc., Healthcare stocks news, , Read more ...
Provides Preliminary Revenue Range for the First Quarter 2020 Withdraws Prior 2020 Annual Revenue Guidance PLEASANTON, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG), today provided an update on the actions it is taking to focus its business operations to su...
PLEASANTON, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors. She bri...
Investment Thesis 10x Genomics ( TXG ) looks like a promising play within the expanding gene sequencing sector. The company posted a strong set of full-year financials with sales up by 68% from 2018 to $245.9 million, with its consumables division driving $206.9 million of this figure and in...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead. Formed by New Enterprise Associate's orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a $301 million market cap. The Boston-based company's sol...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...